PredicineCARE
CLIA-certified 200-gene cfDNA assay for treatment selection and comprehensive molecular profiling in solid tumors.
- Developer
- Predicine
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- Plasma, Whole blood
- Molecular modality
- DNA mutation
- Current version
- PredicineCARE current 200-gene configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.